Personal Healthcare Budgets: Sheffield

Lord Blunkett Excerpts

Wednesday 4th September 2019 Lords Chamber

Asked by

[Lord Blunkett]

To ask Her Majesty’s Government what was the difference in the number of people covered by personal health care budgets or Independent Living Fund payments in Sheffield between (1) January and June 2019, (2) January and June 2018, (3) January and June 2017, and (4) January and June 2015.

[The Parliamentary Under-Secretary of State, Department of Health and Social Care (Baroness Blackwood of North Oxford) (Con)]

My Lords, the department does not collect the data requested in the specified format. However, the number of people with a personalised health budget is calculated on a quarterly basis within each financial year, which ends on 31 March. Currently, 53,143 people benefit from a personal health budget nationally. I shall write to the noble Lord this afternoon with a full breakdown of all the data that we collect in relation to Sheffield and place a copy of the letter in the Library.

[Lord Blunkett (Lab)]

I am grateful to the Minister. Can she help me with a very practical question relating to the county council’s publication last week, and that of the Institute for Government today, in respect of the funding of social and the interim grant that was due to run out at the end of March next year, which constituted a third of government spending? Can we presume that the amount announced by the Chancellor of the Exchequer this afternoon is in addition to renewing that temporary grant? If it is, is it not a strange paradox that it is half a billion pounds less than the amount that he announced in respect of a no-deal arrangement with the European Union?

[Baroness Blackwood of North Oxford]

The noble Lord has asked a very important question and I am pleased that the Prime Minister has followed through on his commitment to improve the situation for local authorities and for social care, not only by increasing funding for social care by £1 billion today but by increasing funding for local authorities. This is a welcome change for local authorities, which need to ensure that they can fund the commitments that we have. In addition to the letter that I shall place in the Library, I shall be happy to follow up on the specific challenge that the noble Lord raised regarding Sheffield following Questions.

Cannabis-based Medicines

Lord Blunkett Excerpts

Thursday 21st June 2018 Lords Chamber

[Lord O’Shaughnessy]

The noble Baroness makes excellent points. I know she has been deeply involved in the Alfie Dingley case and I thank her for her work on that. What we are discovering is that it is not the case that just one drug is going to fix this for the 200,000 people who are suffering. There is a need for variety. So it cannot be the case that just because one thing is licensed it is used for everyone; it needs to be specific to the needs of the patient, which is the noble Baroness’s main point. The interim panel is there precisely to make decisions on an individual basis. It is a patch to the system, if you like, not a long-term change, which is why the review is in place so that we can ensure that many other products derived from cannabis, if they are proven to have therapeutic benefits, can be developed into drugs for the range of needs that are out there.

[Lord Blunkett (Lab)]

My Lords, 15 years ago trials were undertaken, one of which led to a separate authorisation of a derivative from cannabis for MS sufferers. I have not been clear on this from any of the reporting, so will the Minister say what trials are currently taking place in this country that could be brought to fruition? What evidence can we very quickly obtain from trials and evidence of legitimate use for medicinal purposes from the rest of the democratic world? How can it possibly be justifiable for us to provide 45% of usage for derivatives from cannabis grown in this country but not to be able to use it ourselves?

[Lord O’Shaughnessy]

The noble Lord speaks with great wisdom on this topic. The problem, as he knows, is that these drugs have been in Schedule 1 and, although in theory that allows for research, in reality it creates a very cautious environment that makes research difficult. That means that apart from Sativex, which has been licensed, and Epidiolex, which is in the process of being licensed, there are very few, if any, other drugs actually going through the clinical trials process in this country because of the very tight rules that have governed usage. Other countries have of course relaxed their rules and developed that evidence, and it is precisely that kind of evidence base that will be considered by Professor Davies in her review.

Chronic Lymphocytic Leukaemia: Ibrutinib

Lord Blunkett Excerpts

Thursday 7th June 2018 Lords Chamber

[Lord O'Shaughnessy]

I thank the right reverend Prelate for that question. As he will know, NICE consults widely with patient groups and others in making its decisions. I am not clear at this stage whether NHS England met patient groups and others in designing its clinical commissioning guidelines, which is of course what I shall investigate next week.

[Lord Blunkett (Lab)]

First, I commend the Minister for being prepared to come to the noble Baroness Jowell’s funeral last week, which was greatly appreciated. Secondly, I commend him for his obvious commitment and detailed understanding on this particular issue that has been raised this morning. Is it not exactly the same issue as Baroness Jowell was raising, although on a very different treatment and challenge, which is that the best and most appropriate treatment should be available as quickly and easily as possible everywhere and to everyone, wherever they live?

[Lord O'Shaughnessy]

I am grateful to the noble Lord for that. I was privileged to be invited to the funeral, which was a very moving occasion for a very special lady. On his overall point, NICE approves 71% of cancer drugs that are applied for, so there is an absolute focus on making sure that the most effective cancer drugs can be brought to patients in England as soon as possible. Under the reformed cancer drugs fund, that can now happen from the point at which there is a draft guideline, which is often many months before it would otherwise be the case. That means that tens of thousands of people have been able to access cancer drugs earlier than they would ever have done before and, as a consequence, many lives have been saved.

Children: Obesity

Lord Blunkett Excerpts

Thursday 10th May 2018 Lords Chamber

[Lord O'Shaughnessy]

It goes to show that public health campaigns can be effective. I remember the “Go to work on an egg” campaign—although I had a banana myself. The serious point is that too many children do not go to school after a proper breakfast, and one of the great advances with the sugar levy has been a commitment of around £26 million to support breakfast clubs in about 1,500 schools in areas that unfortunately have the worst outcomes for healthy children and obesity. That support will help those children go to school on a good breakfast and function properly.

[Lord Blunkett (Lab)]

Does the Minister agree that one of the tragedies of the demise of so many Sure Start programmes was that parents were engaged in not just nurturing but understanding what happened to their children, particularly in poor areas where junk food was bought as opposed to learning to cook? Will he put some emphasis on parents being taught how to cook nutritious food, and not just children?

[Lord O'Shaughnessy]

I could not agree with the noble Lord more about the importance of good parenting and parents setting an example in this area. I would focus on a major Public Health England initiative, Change4Life, which is about equipping parents with the knowledge and understanding of how to prepare good-quality, healthy meals that are affordable.

Children: Obesity

Lord Blunkett Excerpts

Thursday 19th April 2018 Lords Chamber

[Lord O’Shaughnessy]

Following the debate that we had the other day, I looked up the Daily Mile online. It is now in 2,000 schools across the UK. My right honourable friend the Secretary of State has described it as an excellent initiative, which indeed it looks like. It certainly seems to develop good habits of physical and mental health. Writing to schools is of course a matter for the Department for Education, but I will certainly speak to my colleagues in that department to encourage schools to take this up. In the spirit of the debate of the noble Baroness, Lady Walmsley, I think it would be better to end with a quote from William at Woodfield Primary School in Wigan, who said that the Daily Mile,

“helps you with your maths, English, and you get faster each time, which makes you healthier”.

What more could you want?

[Lord Blunkett (Lab)]

My Lords, I cannot match the alliteration of the Minister but I ask him if he and his colleagues in other departments would consider an addition to the sport, to the dietary and to the drive against sugar, given the evidence of the recent review that the Government undertook into full-time social youth action in which organisations such as Volunteering Matters and City Year UK demonstrate that work by young people for young people against bullying, emotional trauma and mental health problems can have a real effect.

[Lord O'Shaughnessy]

I completely agree with the noble Lord. I believe that he chairs the National Citizen Service, which has been a massive initiative to encourage such habits in teenagers. I completely concur with him: the Government take a number of approaches to encourage youth social action, and that is something that we will continue to support.

NHS: Cancer Treatments

Lord Blunkett Excerpts

Thursday 25th January 2018 Lords Chamber

[Lord Blunkett (Lab)]

My Lords, this is the greatest privilege, and one of the most daunting moments of my life—to follow my noble friend, with the eloquence, the care, the compassion and the courage she has shown. She is my noble friend—not by affiliation or values, although we share them—but through a lifelong friendship that has lasted for well over 40 years.

If the House will forgive me, I want to say a word about Tessa—the noble Baroness, Lady Jowell—as a person. We got to know each other when we both chaired our respective social services committee. That is when I saw to begin with her care and compassion, described so well this afternoon. It is a compassion that has overcome the challenges that she faces and those of her family. Yesterday on the “Today” programme, and she said it this afternoon about the community of care, it was not just her own courage that shone through; it was the deep love and affection of her family—David, Jess and Matthew, and her extended family. The care she displayed this afternoon reached out, because it is the caring family and the community around those with cancer who travel on the journey as well. It is the love and hope that they give that reaches out.

Sally, the young mother on the “Today” programme yesterday, as with the experience of the noble Baroness, Lady Rebuck, whose husband Philip I knew well and saw just three days before he died, displayed the search for excellence, for innovation and, above all, for action, that my noble friend has called for this afternoon.

I know absolutely nothing about the ECI—but I will. There is a need to set aside bureaucracy in terms of the experimentation that patients who are on this journey wish to try, to set aside the usual processes and to share the best practice from wherever it comes. Part of the role of family is to enable people to be able to sustain themselves while they seek access to that innovation and that improvement, and to know about where excellence exists here and across the world. Who you know is so often—too often—the telling point when you are seeking the best that exists in scientific development. What my noble friend Lady Jowell, my friend Tessa, has said this afternoon is that this should be available whoever you know, wherever you are and whatever access you have had to other people’s knowledge. The breakthroughs across the world need to be made available as quickly and with as little bureaucracy in our health service as possible.

My noble friend mentioned 24 May last year, when she was on the way to a Sure Start programme. She and I—when she was the first designated Public Health Minister and I had education and employment—started the Sure Start programme. We both went on a journey through to Cabinet—she exemplified her own wonderful networking skills in helping us to win the Olympics for London and their implementation, which shone across the world, and I had all sorts of different guises, good and bad. That journey has, for Tessa, my noble friend, always been about support, care and reaching out to others. When terrible terrorist attacks have taken place, not just here but across the world, she has cared about those families, just as her family now care about her. We are, all of us, privileged to be here this afternoon and to have heard her speak. She has given us a clarion call to pick up that cudgel and work tirelessly to ensure that what she seeks is carried forward for others in the future, and that our NHS, our scientists, our innovators and our consultants can draw down on the experience from across the world and can remember Tessa Jowell as we all will, and who we are privileged to have heard this afternoon.